---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Wakefulness-promoting agents for residual sleepiness"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Wakefulness-promoting agents for residual sleepiness. Topics: VA/DoD 2025 recommendation for armodafinil, modafinil, or solriamfetol; Confirming adherence and efficacy of airway treatment before adding a wake-promoting agent; Solriamfetol label: indication and limitation of use in OSA; Armodafinil label: indication and limitation of use in OSA; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/wakefulness-promoting-agents-for-residual-sleepiness"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Wakefulness-promoting agents for residual sleepiness

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Wakefulness-promoting Agents for Residual Sleepiness

<a id="topic-2.2.2.1.7-1"></a>

### VA/DoD 2025 recommendation for armodafinil, modafinil, or solriamfetol

> “For treatment of obstructive sleep apnea-related residual excessive daytime sleepiness in patients who are optimally treated with sufficient therapy use, we suggest adding:”
> “Moderate quality evidence suggests that both modafinil and armodafinil improve the critical outcomes of sleepiness and quality of life (QoL).(224)”
> “Moderate quality evidence suggests that solriamfetol improves sleepiness.(224) High-quality evidence suggests that solriamfetol improves QoL.(226)”
> “considerations include caution against prescribing armodafinil, modafinil, or pitolisant in patients with cardiovascular disease.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.7-2"></a>

### Confirming adherence and efficacy of airway treatment before adding a wake-promoting agent

> “Therefore, treating providers should confirm that patients are using their treatment for OSA during the entire sleep period before considering addition of a wake-promoting agent.”
> “Insufficient sleep is very common in the general population and must be ruled out as a cause of EDS prior to prescribing wake-promoting agents.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

<a id="topic-2.2.2.1.7-3"></a>

### Solriamfetol label: indication and limitation of use in OSA

> “SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA)”
> “SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness.”

Source: [Axsome Sunosi prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211230s009lbl.pdf)

<a id="topic-2.2.2.1.7-4"></a>

### Armodafinil label: indication and limitation of use in OSA

> “NUVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD).”
> “In OSA, NUVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction.”

Source: [Teva Nuvigil prescribing information (2017)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf)

<a id="topic-2.2.2.1.7-5"></a>

### Wake-promoting agents outside the scope of the ERS 2021 guideline

> “In addition, several drugs address the problem of residual sleepiness despite optimal treatment of the underlying disease [103–105]. Unfortunately, these findings could not be included in this project as they do not focus on the causal treatment of the disease itself and major studies were published after the time limit of the literature searches.”

Source: [Randerath et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9489103/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
